Galderma Laboratories sued Lupin Inc. for patent infringement related to their respective doxycycline products. The lawsuit centered on whether Lupin's abbreviated new drug application (ANDA) infringed Galderma's patents. A district court found no infringement, a decision upheld by the Federal Circuit Court of Appeals. The appeals court agreed with the lower court's assessment of the presented evidence, particularly regarding the reliability of dissolution tests used to demonstrate infringement. The court determined that Galderma failed to prove infringement under the doctrine of equivalents. Ultimately, the appeals court affirmed the lower court’s judgment in favor of Lupin.